GILBERT, Ariz., Aug. 19, 2014 /PRNewswire/ -- A cutting-edge research study at Banner MD Anderson Cancer Center is testing the safety and effectiveness of a new investigational drug that, when combined with chemotherapy, may make a major difference in treating breast cancer in patients who carry harmful mutations on either the BRCA1 or BRCA2 genes.
The Brocade Study will enroll patients with hereditary breast cancer that is metastatic, meaning it has spread to other parts of the body, or locally recurrent, meaning it has come back in the same original area. These patients also have mutations in the BRCA1 or BRCA2 genes, similar to the kind that actress Angelina Jolie inherited. The study is examining the results of the oral drug Veliparib when taken in combination with chemotherapy treatments.
"These breast cancers can be very difficult to treat with traditional chemotherapy regimens. If Veliparib is found to add to the effectiveness of chemotherapy, it would give patients with BRCA mutations and metastatic breast cancer a new option for therapy," said Mary Cianfrocca, MD, director of the Breast Cancer Program and medical director of the Clinical Cancer Genetics Program at Banner MD Anderson. Dr Cianfrocca is also the principal investigator for the Brocade Study at Banner MD Anderson.
Veliparib is designed to prevent the cancer cell from repairing itself by blocking a protein called PARP, possibly making the cell more susceptible to anti-cancer drugs. Banner MD Anderson is the only health care facility in Arizona which is offering the study. To learn more about the BROCADE study call 480-256-3420 or visit, www.brocadestudy.com.
Banner MD Anderson, located on the Banner Gateway campus, delivers cancer care to patients in Arizona through the collaboration of Banner Health and The University of Texas MD Anderson Cancer Center. Banner MD Anderson offers focused disease-specific expertise in the medical, radiation and surgical management of the cancer patient. The center uses an evidence-based, multidisciplinary approach to patient care, and provides access to clinical trials and new investigative therapies. Banner MD Anderson also offers state-of-the-art technology for diagnosing, staging and treating all types of cancer. For more information, visit www.BannerMDAnderson.com.
Contact: Public Relations
SOURCE Banner MD Anderson Cancer Center